These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 1458193)

  • 21. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with Parkinson's disease].
    Milejski P; Orzechowska-Juzwenko K; Kamienowski J; Horoch E; Niewiński P; Hurkacz M; Rzemisławska Z
    Neurol Neurochir Pol; 1999; 33(5):1015-24. PubMed ID: 10672554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for polymorphic oxidation of sparteine in Japanese subjects.
    Ishizaki T; Eichelbaum M; Horai Y; Hashimoto K; Chiba K; Dengler HJ
    Br J Clin Pharmacol; 1987 Apr; 23(4):482-5. PubMed ID: 3580254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.
    Brøsen K; Davidsen F; Gram LF
    Br J Clin Pharmacol; 1990 Feb; 29(2):248-53. PubMed ID: 2306418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sparteine oxidation polymorphism: phenotyping by measurement of sparteine and its dehydrometabolites in plasma.
    Paar WD; Schuhler H; Fimmers R; Dengler HJ
    Eur J Clin Pharmacol; 1989; 36(6):555-60. PubMed ID: 2590312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic disposition of ajmaline.
    Köppel C; Tenczer J; Arndt I
    Eur J Drug Metab Pharmacokinet; 1989; 14(4):309-16. PubMed ID: 2633926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical significance of genetically determined polymodality of the distribution of quinidine elimination rates].
    Kholodov LE; Glezer MG; Makharadze RV; Kunchuliia LSh; Sokolov AV
    Kardiologiia; 1988 Feb; 28(2):56-9. PubMed ID: 3373950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sparteine oxidation polymorphism: a family study.
    Brøsen K; Otton SV; Gram LF
    Br J Clin Pharmacol; 1986 Jun; 21(6):661-7. PubMed ID: 3741716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans.
    Schellens JH; Ghabrial H; van der Wart HH; Bakker EN; Wilkinson GR; Breimer DD
    Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):520-8. PubMed ID: 1934865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sparteine oxidation polymorphism in Denmark.
    Brøsen K; Otton SV; Gram LF
    Acta Pharmacol Toxicol (Copenh); 1985 Nov; 57(5):357-60. PubMed ID: 4090995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of site-specified tritium labelling to confirm the formation of 17-oxosparteine as a minor urinary metabolite of sparteine in man.
    Ritchie JC; Mitchell SC; Smith RL; Zhang AQ
    Xenobiotica; 1996 Sep; 26(9):977-82. PubMed ID: 8893044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.
    Nielsen MD; Brøsen K; Gram LF
    Br J Clin Pharmacol; 1990 Mar; 29(3):299-304. PubMed ID: 2310654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans.
    Eichelbaum M; Woolhouse NM
    Eur J Clin Pharmacol; 1985; 28(1):79-83. PubMed ID: 3987789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sparteine oxidation is practically abolished in quinidine-treated patients.
    Brinn R; Brøsen K; Gram LF; Haghfelt T; Otton SV
    Br J Clin Pharmacol; 1986 Aug; 22(2):194-7. PubMed ID: 3756067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sparteine metabolism in a Nigerian population.
    Ritchie JC; Mitchell SC; Smith RL
    Drug Metabol Drug Interact; 1996; 13(2):129-35. PubMed ID: 8905244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benzbromarone biotransformation is not related to polymorphic oxidation of sparteine.
    Walter-Sack I; Eichelbaum M; de Vries JX; Weber E
    Klin Wochenschr; 1988 Nov; 66(21):1097-8. PubMed ID: 3236759
    [No Abstract]   [Full Text] [Related]  

  • 36. A simple borohydride/GC method for measuring sparteine metabolites in man.
    Inaba T; Vinks A; Otton SV
    Br J Clin Pharmacol; 1986 May; 21(5):473-80. PubMed ID: 3718806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid determination of sparteine and its metabolites in urine.
    Veningerová M; Prachar V; Lukácsová M; Glasa J; Holomán J
    J Chromatogr; 1993 Dec; 622(2):274-7. PubMed ID: 8150877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymorphic sparteine metabolism and amyotrophic lateral sclerosis.
    Kaneko K; Atsumi T; Miyatake T
    J Neurol; 1989 Dec; 236(8):452-5. PubMed ID: 2614489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Stereospecific hydroxylation of (+)-sparteine (pachycarpine) in the rat].
    Ebner T; Eichelbaum M; Fischer P; Meese CO
    Arch Pharm (Weinheim); 1989 Jul; 322(7):399-403. PubMed ID: 2783013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thin-layer chromatographic screening test for polymorphic sparteine oxidation.
    Ebner T; Meese CO; Eichelbaum M
    Ther Drug Monit; 1989; 11(2):214-6. PubMed ID: 2718225
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.